Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 306612
GP2 is an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The patents are titled Vaccine for the Prevention of Breast Cancer Recurrence, and, Targeted Identification of Immunogenic Peptides.
GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. In a Phase IIb clinical trial completed in 2018, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months.
Following breast cancer surgery, a HER2/neu 3+ patient receives Herceptin in the first year, with the hope that their breast cancer will not recur, with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting while Kadcyla has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting.
Patent 1 –
Title Vaccine for the Prevention of Breast Cancer Recurrence
Provisional Patent Application No. 61/121,220
Patent 2 –
Title Targeted Identification of Immunogenic Peptides
as described in U.S. Patent Application No. 12/045,402 filed on 3/10/2008 and Australian Application No. 2008201427 filed on 3/28/2008, both claiming priority to U.S. Provisional Application No. 60/714,865 filed on 09/08/2005 and International Application No. PCT/US2006/035171 filed on 09/08/2006; and
as described in International Application No. PCT/US2006/035171 filed on 09/08/2006 and all corresponding National Stage Applications including but not limited to Japanese Patent Application No. 2008-530244, European Patent Application No. 06824918.4 filed on 3/31/2008, and Canadian Patent Application No. 2,622,036 filed on 3/10/2008; and
as described in International Application No. PCT/GB2008/050227 filed 03/28/2008 and all its corresponding National Stage Applications
The Field means (a) all fields of use with respect to Patent titled Vaccine for the Prevention of Breast Cancer Recurrence; and (b) use of the HER family peptide GP2 in combination with HerceptinÂ® and only in the field of human therapeutics with respect to Patent titled Targeted Identification of Immunogenic Peptides.
This agreement is in support of the GP2 breast cancer vaccine Phase II clinical trial.
Licensee believes that GP2 may be used to address the 50% of recurring cancer patients who do not respond to either Herceptin or Kadcyla in the treatment of breast cancer.
IPSCIO Record ID: 310513
Ii-Key is a peptide derived from the major histocompatibility complex (MHC) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. T cells recognize antigenic epitopes when they are â€˜presentedâ€™ to them by specific molecules, termed (MHC) on the surface of infected or malignant cells. This interaction activates the T cells, stimulating a multicellular cascade of actions that eliminates the diseased cell and protects against future disease recurrence.
In 2006 Phase I clinical trial was completed of AE37 in breast cancer, including a phase Ib safety and immunology study of AE37 in combination with GM-CSF in 16 breast cancer patients who had completed all first-line therapies and who were disease-free at the time of enrollment to the study (Holmes et al. Results of the first phase I clinical trial of the novel Ii-Key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;263426-33).
The Foundation conducted the study, under the sponsorship of an institute affiliated with the United States Military until the IND #12229 was transferred to the Company, after which Foundation continued trial management on behalf of the Company.
The Foundation is a nonprofit organization dedicated to advancing medicine by administering, managing and supporting preeminent scientific programs.
Licensee is an oncology company focused on the modulation of the immune system to treat cancer and is developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key.
IPSCIO Record ID: 322039
Licensor granted Licensee an exclusive license to commercialize Tukysa (tucatinib) for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Licensor will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Licensor will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan.
Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor to treat a type of breast cancer.
HER2-positive cancers is a protein that can promote the growth of breast cancer cells. Breast cancer cells with high levels of HER2 are called HER2-positive.
Licensor is a biotechnology company that study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases including cancer.
HER2-positive breast cancer is a type of breast cancer in which breast cancer cells have a protein receptor called HER2 (human epidermal growth factor receptor 2).
Licensee is a premier research-intensive biopharmaceutical company that researches medicines and vaccines to prevent and treat diseases including cancers.
IPSCIO Record ID: 344536
The licensed intellectual property includes the following patents
— Methods And Compositions For Stimulating T-Lymphocytes
— Compositions Containing Immunogenic Molecules and Granulocyte-Macrophage Colony Stimulating Factor, as an Adjuvant
— Controlled modulation of amino acid side chain length of peptide antigens
— Vaccine for the Prevention of Breast Cancer Relapse
IPSCIO Record ID: 369313
The Field of Use shall mean in vivo, ex vivo, or in vitro prophylactic or therapeutic uses of Licensed Product in the treatment or prevention of cancer in humans.
IPSCIO Record ID: 369382
– an exclusive license, including the right to sublicense, under the Licensor Patent Rights, to research, develop, make, have made, use, sell, offer for sale, supply, cause to be supplied and import Compounds and Licensed Products in the Territory;
– an exclusive license, including the right to sublicense, to use Licensor Technology and Confidential information in connection with the research. development, making, having made, use, sale, oiler for sale, supply, causing to be supplied and importation of Compounds and Licensed Products in the Territory;
– an exclusive license, including the right to sublicense, under the Licensor Patent Rights to research, develop, make, have made, use, sell, offer for sale, supply, cause to be supplied and import Diagnostic Assays in the Territory; and
– an exclusive license, including the right to sublicense, to use Licensor Technology and Confidential information in connection with the research, development, making, having made, use, sale, offer for sale, supply, causing to be supplied and importation of Diagnostic Assays in the Territory.
For the Non-Exclusive Research License, Licensor grants a non-exclusive, irrevocable, perpetual license in the Territory, with the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology and Confidential Information disclosed to Licensee during the Term, excluding any Patent Rights relating thereto.
CDX-110 means the EGFRvlll mutant peptide consisting of the amino acid sequence LEU-GLU-GLU-LYS-LYS-GLY-ASN-TYR-V AL-V AL-THR-ASP-HIS covalently linked to a Cysteine and conjugated to keyhole limpet hemocyanin (KLH). CDX-110 is a therapeutic cancer vaccine candidate.
Compound means a peptide that comprises at least a portion of an EGFRvIII comprising the amino acid sequence LYS-LYS-GLY-ASN-TYR. as an antigen. alone or as a component of a larger peptide. protein or molecule.
EGFRvIII means EGFR variant III peptide, a variant of EGFR. previously referred to as a type II variation of EGFR, consisting of the amino acid sequence of EGFR as set forth in GenBank Accession No, CAA2524Q. except amino acids number 1 through 24 have been deleted and where amino acids number 30 through 297 have been replaced by a Glycine. and naturally occurring variants thereof.
Additional Component means a therapeutically active (alone or in combination) adjuvant. immunomodulator. immunoregulator or hapten.
APC Product means an antibody or fragment thereof. that is targeted to an antigen-presenting cell (APC) and that comprises or is connected to a Compound or Licensed Product.
Patents are for the EGFRvlll Patent Family 1, 2, and 3.
Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that begins within the brain.
Rindopepimut is an experimental therapeutic cancer vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII) in patients with Glioblastoma Multiforme (GBM)
IPSCIO Record ID: 189409
The patent describes methods of cancer treatment through the administration of proteins or specific peptides found on tumor stem cells in vivo, in a manner eliciting monocyte or dendritic cell migration in order to allow uptake of proteins or peptides, followed by administration of a maturation signal in vivo. The invention provides for treatment of cancer through induction of anticancer immunity and/or immunity towards tumor initiating stem cells.
IPSCIO Record ID: 30031
KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (HerceptinÂ®) and there is cancer remaining in the tissue removed during surgery.
IPSCIO Record ID: 6674
Norelintm is a therapeutic vaccine designed to stimulate in patients production of antibodies against GnRH, resulting in reduced production of hormones that may cause or contribute to the growth of certain sex-hormone dependent cancers. It has completed a Phase I/II safety and immunogenicity trial in hormone-sensitive prostate cancer suggesting that the approach may be better tolerated than currently available therapies.
Compositions and Treatments for Pneumonia in Animals
Issued U.S. Patent No. 5,849,531 a
Leukotoxin Vaccine Compositions and Uses Thereof
Issued U.S. Patent No. 5,871,750 a
Pasteurella haemolytica Leukotoxin Compositions and Uses Thereof
Issued U.S. Patent No. 5,476,657 a
B. Robins and Associates Patent Series 9001-0016
Enhanced Immunogenicity Using Leukotoxin Chimeras
U.S. Application 08/976,566 a
U.S. Patent 5,708,155 a
U.S. Patent 5,422,110 a
GnRH Leukotoxin Chimeras
U.S. Application 09/383,912 a
U.S. Patent 5,969,126 a
U.S. Patent 5,723,129 a
U.S. Patent 5,837,268 a
U.S. Patent 6,022,960 a
IPSCIO Record ID: 217567
AE37 is an immunotherapeutic vaccine for prostate cancer. AE37, an Ii-Key-Hybrid molecule that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers, including breast, prostate, and bladder cancers.
Trade name AE37
IPSCIO Record ID: 256328
IPSCIO Record ID: 369311
This agreement includes a non-exclusive grant back to Licensor by Licensee.
The Product means BLP25.
BLP25 means Licensors immunotherapeutic vaccine composed of a 25-amino acid sequence of the MUC1 cancer mucin, which vaccine is combined with the adjuvant Lipid A and is encapsulated in a liposomal delivery system, together with any improvements thereto, such as liposomal IL-2 in a kit, synthetic Lipid A, or new delivery formats such as unit dose liquid formulations and unit dose syringes.
MUC1 means cancer associated mucin-1.
L-BLP25 is a synthetic MUC1 peptide vaccine and is a biological response modifier with a chemically synthesized peptide of a cancer-associated protein antigen widely expressed on common cancers. It is designed to induce an immune response to both the synthetic antigen and the natural corresponding antigen as expressed on the cancer.
The field shall mean the use of BLP25 for the prevention and/or treatment of cancers in humans.
IPSCIO Record ID: 364016
Licensor also hereby grants to Licensee an exclusive license to make, use, and/or sell the Licensed Materials in the Territory for the Field of Use. At Licensees request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.
U.S. patent application serial number US 61/033,425 entitled 'Heat Shock Protein GP96 Vaccination and Methods of Using Same' and filed on 20 March 2008;
PCT patent application number PCT/US2009/001727 entitled 'bleat Shock Protein GP96 Vaccination and Methods of Using Same' and filed on 19 March 2009;
all United States patents and foreign patents and patent applications based on these U.S. applications; all divisionals, continuations of the foregoing; and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. patent application serial number US 61/033,425 or PCT patent application number PCT/US2009/001727 to meet the requirements of 35 U.S.C. 112Â¶1; and any re-examinations or reissues of the foregoing.
â€œPatent Rightsâ€ shall mean the following United States Patent applications U.S. patent application serial number US 61/033,425 entitled â€œ Allogeneic Cancer Cell-Based Immunotherapyâ€ and files on 3 March 2008; PCT patent application number PCT/US2009/001330 entitled â€œAllogeneic Cancer Cell-based Immunotherapyâ€ and filed on 3 March 2009; all United States patents and foreign patents and patent applications based on these U.S. applications; all divisionals, continuations of the foregoing; and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. patent application serial number US 61/033,425 or PCT application number PCT/US2009/001330 to meet the requirements of 35 U.S.C. 112Â¶1; and any re-examination or reissues of the foregoing.
IPSCIO Record ID: 263928
IPSCIO Record ID: 364010
Licensor also hereby grants to Licensee an exclusive license to make. use. and/or sell the Licensed Materials in the Territory for Field of Use. At Licenseeâ€™s request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.
Licensor grants to Licensee a six (6) month exclusive option to negotiate a worldwide royalty-bearing, exclusive license with right to sublicense for any Improvement.
Licensed Product shall mean any product or part thereof which
(a) is covered in whole or in part by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights
(b) is manufactured by using a process which is covered in whole or in party by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights or
(c) incorporated or comprises the Podack Cancer Vaccine (UM97-14) or the cell line â€œAD100-gp96/III.Aâ€.
Patent Rights shall mean the following United States Patent applications U.S. provisional patent application serial number 60/075.358 entitled â€œModified Heat Shock Protein-antigenic Peptide Complexâ€ and filed on February 20, 1998 U.S. patent application serial number 09 253.439 entitled â€œModified Heat Shock Protein-Antigenic Peptide Complexâ€ and filed on February 19, 1999 U.S. patent application serial number 11/878.460 entitled â€œRecombinant Cancer Cell Secreting Modified Heat Shock Protein-antigenic Peptide Complexâ€ and filed on July 24, 2008 all United States patents and foreign patents and patent applications based on these U.S. applications all divisionals, continuations of the foregoing and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. provisional patent applications serial number 60/075.358. U.S. Patent application serial number 09 253.439, or U.S. patent application serial number 11/878.460 to meet the requirements of 35 U.S.C. 112Â¶1; and any re-examinations or reissues of the foregoing. â€œPatent Rightsâ€ shall not include Excluded Patent Rights.
Licensed Materials shall mean any modified AD100 cell lines that have been engineered to secrete gp96.
IPSCIO Record ID: 345562
ChAdOx1 and ChAdOx2 are modified simian adenoviral vectors which deliver target antigens into cells to generate a specific immune response. These viruses were originally isolated from chimpanzees to avoid pre-existing immunity issues affecting the use of human adenovirus vectors.
IPSCIO Record ID: 324645
8,114,407 – EphA2 T-cell epitopes and uses therefor
Proprietary Vaccine shall mean a vaccine which is developed or being developed for a therapeutic indication based on biological activity that is solely-owned or in-licensed by Licensee from third parties and which is not covered by the Patent Rights and which is not Licensed Product hereunder. For the avoidance of doubt, the Il-13 Alpha2 Peptide Analogues licensed under the Exclusive Patent License Agreement shall constitute a Proprietary Vaccine.
IPSCIO Record ID: 279358
INNO-305 (WT1) Immunotherapy
Wilms tumor protein, or WT1, is a well known and well characterized protein found in the human body. WT1 is normally produced at the embryonic stage of human development and, as people age, expression of the protein is reduced and nearly eliminated. In normal adults, WT1 is present but at very low levels. However, in the case of certain cancers including, acute myelogenous leukemia, or AML, chronic myelogenous leukemia, non-small cell lung cancer and mesothelioma, the protein is found in very high levels. Because normal levels of WT1 are low and cancer levels of WT1 are high, we believe WT1 is an attractive target for cancer immunotherapy.
IPSCIO Record ID: 256326
This amendment adds for the CRADA Research License, Licensor grants the non-exclusive, worldwide, nontransferable and non-sublicensable license, under the Licensed Intellectual Property, solely as necessary to support research and development activities conducted by the NIH under the CRADA or Cooperative Research and Development Agreement for lntramural-PHS Clinical Research that pertain to certain Collaboration Compounds.
GI-4000 means the series of Tarmogen products that express mutated Ras and/or one or more peptides thereof. GI4014, GI-4015, GI-4016 and GI-4020 arc part of the GI-4000 series and are the subject of [IND No. BB-IND 11653].
GI-6200 means the series of Tarmogen products that solely express human carcinocmbryonic antigen (CEA). GI6207 is part of the GI-6200 series and means the single Tarmogen product that is the subject of [IND No. BB-IND 13934 (drug master file BB-MF 13884)], and that solely expresses human CEA having a N6lOD mutation.
GI-6l00 means the series of Tarmogen products that express human MUC- I antigen(s). GI-6108 is part of the GI-6l00 series and is the single Tarmogen product that is the current lead product for the GI-6100 program. GI-6108 is currently undergoing preclinical development at the National Institutes of Health under the terms of the CRADA. As of the Amendment #5 Effective Date, GI-6l08 is believed to be the specific product intended to be subject of [an IND to be filed by the NIH under the CRADA. Should a different Tarmogen product expressing MUC-1 antigen(s), other than GI-6108, be selected for said IND], then it is understood such product shall become the Drug Candidate associated with the GI-6100 designation.
Gl-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that is the subject of [BB-IND 14895].
GI-4000 series target tumors with mutations in a protein called Ras.
IPSCIO Record ID: 280840
Licensor hereby grants to Licensee a non-exclusive license in the Territory under Licensorâ€™s rights in the Know-How to use and practice any method, process, or procedure within the Know-How and otherwise use and exploit the Know-How; all in the Licensed Field; provided however, that with respect to Project Information, such non-exclusive license shall be limited to the Project Information Licensed Field.
Licensed Patents means
Patent Applications 61/249,596; 61/423,842; 61/423,825; 61/392,296; 61/423,832; 61/254,395; 61/423,838
Drug summary Liposome-packaged combination of proprietary molecule, inhibitor of multidrug resistance transporter, and conventional chemotherapeutic agent.
Potential use adjuvant applied as part of chemotherapy of cancer patients.
Drug summary Adenovirus-based treatment inducing immune response. Ready for final stage of preclinical development.
Potential use Universal anti-cancer vaccine.
Drug summary Androgen receptor inhibitor, prepared for Hit-2-Lead optimization studies.
Potential use Nanodrugs for treatment of prostate cancer (both hormone (androgen)-dependent and â€“independent/refractory forms).
Drug summary MYC inhibitor.
Potential use Drugs for treatment of a broad range of solid tumors (breast, prostate, colon, non-small cell lung carcinoma, etc.) and hematological malignancies.
Projects and Licensed Patents
Mobilan = Research, development and support of an immunotherapeutic drug candidate based on recombinant adenovirus vector, stimulating immune response in humans as a vaccine-like treatment for cancer or other indications.
Revercom = Research, development, formulation and support of a drug candidate based on proprietary Reversan compound as an adjuvant for chemotherapy.
Antimycon = Research, development, lead optimization, formulation and support of a drug candidate regulating cMyc transcription factor for cancer indications.
Arkil = Research, development, lead optimization, formulation and support of a drug candidate regulating androgen receptor for prostate cancer.
Xenomycin = Research, development, lead optimization, formulation and support of a drug candidates based on proprietary Curaxin family of compounds for anti-infective/anti-biotic/anti-fungal applications.
2. Licensed Patents
MOBILAN = Use of Toll-Like Receptor and Agonist for Treating Cancer
Andrei Gudkov (RPCI, CBLI)
MOBILAN = Toll-like receptor 5 agonist produced and secreted by mammalian cells
Andrei Gudkov (RPCI), Venkatesh Natarajan (RPCI)
MOBILAN = Functional bacreriophage-based nanoparticles coated by Toll-like receptor 5 agonist
Andrei Gudkov (RPCI, CBLI), Venkatesh Natarajan (RPCI)
ANTIMYCON = Small molecules inhibiting oncoprotein MYC
Andrei Gudkov (RPCI), Catherine Burkhart (CBLI), Mikhail Nikiforov (RPCI), Michelle Haber (CCIA), Murray Norris (CCIA)
ANTIMYCON = Small Molecules Inhibiting Oncoprotein MYC
Andrei Gudkov (RPCI), Catherine Burkhart (CBLI), Mikhail Nikiforov (RPCI), Michelle Haber (CCIA), Murray Norris (CCIA)
ARKIL = Method for treating androgen receptor positive cancers
Katerina Gurova (RPCI), Natalia Narizhneva (CBL)
REVERCOM = Dual cargo nanoparticles combining MRP1 inhibitors with chemotherapeutic drugs
Andrei Gudkov (RPCI, CBLI), Aridam Sen (RPCI), Catherine Burkhart (CBLI), Padmaja Kunapuli (RPCI)